Atlas Trials

A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC

Clinical trial NCT04286958 · UNKNOWN

Trial details

NCT number
NCT04286958
Sponsor
Hebei Medical University Fourth Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Esophageal Cancer
Start date
2020-04-22
Primary completion
2022-12-22
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.